Phase 2 Completed N=50 Randomized Triple-blind Basic Science

Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana

Smoking, Marijuana

Source: ClinicalTrials.gov NCT01844687 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2017

Primary outcomePrimary: Mood Scale - Subscale 'Feeling High' — 4.35; 2.48; 0.39; 6.55 units on a scale VAS 1-100 mm

Summary

The objective of this study is to assess the effects of oral cannabidiol (CBD; 0, 200, 400, 800 mg) on smoked marijuana's (0, 5.6% THC) subjective, reinforcing, cognitive, and cardiovascular effects. This experiment is expected to reveal CBD's intrinsic effects when combined with placebo marijuana, as well as its ability to modulate the behavioral effects of active marijuana.

Outcome Measures

Outcome	Result	p-value
PRIMARY Mood Scale - Subscale 'Feeling High'	4.35; 2.48; 0.39; 6.55; 0.42; 0.32	—

Eligibility Criteria

Inclusion Criteria

Adults between the ages of 18 and 50.
Current marijuana use: Minimum of four times per week, 0.5 joints per occasion during the preceding 4 weeks.
Able to perform study procedures
Women practicing an effective form of birth control

Exclusion Criteria

Female subjects who are currently pregnant or breastfeeding.
Current, repeated illicit drug use other than marijuana
Presence of significant medical illness
History of heart disease
Request for drug treatment
Current parole or probation
Recent history of significant violent behavior
Major psychiatric disorder

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01844687). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.